[ad_1]
Milford, Massachusetts-based Waters Company (WAT) is a worldwide chief in analytical devices and laboratory applied sciences. Valued at a market cap of $21.4 billion, the corporate’s services and products are broadly utilized in industries akin to prescribed drugs, life sciences, meals and beverage, environmental testing, and supplies evaluation to make sure high quality, security, and regulatory compliance. It’s anticipated to announce its fiscal Q3 earnings for 2025 earlier than the market opens on Tuesday, Nov. 4.
Earlier than this occasion, analysts anticipate this healthcare firm to report a revenue of $3.21 per share, up 9.6% from $2.93 per share within the year-ago quarter. The corporate has a promising trajectory of constantly beating Wall Avenue’s bottom-line estimates in every of the final 4 quarters. Its earnings of $2.95 per share within the earlier quarter topped the consensus estimates by a slight margin.
For fiscal 2025, analysts anticipate WAT to report a revenue of $12.99 per share, representing a 9.5% improve from $11.86 per share in fiscal 2024. Moreover, its EPS is predicted to develop 9.2% year-over-year to $14.18 in fiscal 2026.
Shares of WAT have underperformed the S&P 500 Index’s ($SPX) 16.9% return over the previous 52 weeks, with its shares up 9.8% over the identical timeframe. Nonetheless, it has outpaced the Well being Care Choose Sector SPDR Fund’s (XLV) 2.3% downtick over the identical time interval.
Regardless of posting better-than-expected Q2 adjusted EPS of $2.95 and income of $771.3 million, shares of WAT plunged 1.6% on Aug. 4. The decline got here as buyers shifted their consideration to considerations over the corporate’s deliberate acquisition of Becton, Dickinson and Firm’s (BDX) biosciences and diagnostics unit, which many seen as a high-priced buy of a weaker enterprise with potential integration challenges.
Wall Avenue analysts are reasonably optimistic about WAT’s inventory, with an total “Average Purchase” score. Amongst 15 analysts overlaying the inventory, 5 advocate “Sturdy Purchase,” and 10 counsel “Maintain.” The imply worth goal for WAT is $362.36, indicating a marginal potential upside from the present ranges.
On the date of publication, Neharika Jain didn’t have (both immediately or not directly) positions in any of the securities talked about on this article. All data and information on this article is solely for informational functions. This text was initially printed on Barchart.com
[ad_2]
